Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly …
P Wijermans, M Lubbert, A Bosly, C Ravoet… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that
has shown a 50% response rate in a small phase II study in elderly patients with high-risk …
has shown a 50% response rate in a small phase II study in elderly patients with high-risk …
[引用][C] Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly …
P WIJERMANS, M LÜBBERT… - Journal of clinical …, 2000 - pascal-francis.inist.fr
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk
myelodysplastic syndrome : A multicenter phase II study in elderly patients CNRS Inist …
myelodysplastic syndrome : A multicenter phase II study in elderly patients CNRS Inist …
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly …
P Wijermans, M Lübbert, G Verhoef… - Journal of clinical …, 2000 - pubmed.ncbi.nlm.nih.gov
Purpose 5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has
shown a 50% response rate in a small phase II study in elderly patients with high-risk …
shown a 50% response rate in a small phase II study in elderly patients with high-risk …
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly …
P Wijermans, A Ferrant, M Lubbert… - Journal of Clinical …, 2000 - dial.uclouvain.be
Purpose: 5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has
shown a 50% response rate in a small phase It study in elderly patients with high-risk …
shown a 50% response rate in a small phase It study in elderly patients with high-risk …
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly …
P Wijermans, M Lübbert, G Verhoef, A Bosly… - Journal of Clinical …, 2000 - europepmc.org
Purpose 5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has
shown a 50% response rate in a small phase II study in elderly patients with high-risk …
shown a 50% response rate in a small phase II study in elderly patients with high-risk …
Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly …
P Wijermans, M Lübbert, G Verhoef, A Bosly… - Journal of Clinical …, 2000 - cir.nii.ac.jp
抄録< jats: p> PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA
hypomethylating agent that has shown a 50% response rate in a small phase II study in …
hypomethylating agent that has shown a 50% response rate in a small phase II study in …
[引用][C] Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly …
P WIJERMANS - J Clin Oncol., 2000 - cir.nii.ac.jp
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk
myelodysplastic syndrome : a multicenter phase II study in elderly patients | CiNii Research …
myelodysplastic syndrome : a multicenter phase II study in elderly patients | CiNii Research …